Starting Rituximab Treatment for Multiple Sclerosis: A Patient’s Perspective

admin avatar

by admin |

Share this article:

Share article via email

In Sweden, researchers reported in an observational study that Mabthera (rituximab), a widely approved drug for treating lymphoma and/or rheumatoid arthritis, is highly effective in treating multiple sclerosis (MS) and is increasingly being used outside of its approved indications to treat relapsing-remitting MS patients.

In this video from MommyGeeksOut, follow her in one of her multiple sclerosis (MS) diaries and learn how “Mommy” started on Rituximab treatment for MS.

“After having to stop Tysabri treatments last fall because I tested positive for the JC virus and was a high risk for a brain infection, I had to change MS therapies. I tried and failed with Gilenya and Tecfidera so Rituximab also known as Rituxan is my last hope! Here is the vlog of my first treatment!”

Learn more about this: Lymphoma Drug, Rituximab, Highly Effective in Treating Relapsing MS.

Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Questions to Ask Your Doctor If You’re Newly Diagnosed

Illustration of doctor an patient talked
We consulted some of our community contributors at MS News Today and came up with 12 questions people should consider asking their doctors after an MS diagnosis.

Check it out by clicking here.

Dancing Doodle

Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These audio news stories give our readers an alternative option for accessing information important for them.

Listen Here